FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761911056> ?p ?o ?g. }

• W2761911056 endingPage "e15753" @default.
• W2761911056 startingPage "e15753" @default.
• W2761911056 abstract "e15753 Background: REOLYSIN is an immuno-oncology-reoviral agent that induces an inflamed tumor phenotype secondary to viral infection of cancer cells. In combination with chemotherapy, it achieves 1 & 2 year-survival rates of 46% & 24% in MAP pts, respectively. Tumor analysis from pts showed reovirus protein replication, T-cell infiltration and upregulation of PD-L1. Similarly, the combination of REOLYSIN with anti-PD-1 antibody documented survival benefit in a pre-clinical model. We hypothesized that REOLYSIN in combination with chemo and pembrolizumab in pts with MAP would be clinically efficacious. Methods: A phase 2 study (NCT02620423) enrolled MAP pts who progressed after first line treatment. Pts received REOLYSIN (4.5 x 10 10 TCID 50 IV, D1 & D2), plus pembrolizumab (2mg/kg IV, D8) plus either 1)5-FU (LV (200 mg/m 2 /5-FU 200 mg /m 2 IV bolus, 5-FU 1200mg/m 2 continuous IV infusion D1) or 2) gemcitabine (1000 mg/m 2 IV, D1), or 3) irinotecan (125 mg/m 2 IV, D1) q3w, until disease progression/unacceptable toxicity. The primary endpoint was safety. Secondary objectives included tumor response & evaluation for reovirus replication/immune analysis. We report results of safety cohort analysis. Results: 11 pts were enrolled with REOLYSIN, pembrolizumab and gem (n = 6), 5-FU (n = 3), or iri (n = 2). Grade 1 or 2 TEAEs occurred in all pts: fever (64%), headache (55%), chills (46%), fatigue (46%), dehydration (27%), and nausea (27%). In one pt (gem arm), transient Gr 2 increased transaminases was reported on two occasions. Grade 3 or 4 TEAEs occurred in 8 pts (73%): abdominal pain, anemia, arthralgias, biliary obstruction, chills, DVT, diarrhea, fever, hyperglycemia, leukopenia, myalgias, nausea, neutropenia, pulmonary emboli, vomiting. Of the 5 efficacy evaluable pts, one had PR (6 m duration) and 2 SD (lasting 126 and 221 days). Seven died secondary to PD. On-treatment biopsy show reovirus infection in cancer cells and immune infiltrates. Conclusions: The combination therapy showed manageable safety profiles and antitumor activity in previously treated MAP pts. Further evaluation of anti-tumor activity of REOLYSIN and anti-PD-1 antibody ± chemotherapy combos is planned. Clinical trial information: NCT02620423." @default.
• W2761911056 created "2017-10-20" @default.
• W2761911056 creator A5001331899 @default.
• W2761911056 creator A5004814161 @default.
• W2761911056 creator A5005883267 @default.
• W2761911056 creator A5033837903 @default.
• W2761911056 creator A5041071225 @default.
• W2761911056 creator A5052490557 @default.
• W2761911056 creator A5054288328 @default.
• W2761911056 creator A5056309801 @default.
• W2761911056 creator A5081369976 @default.
• W2761911056 date "2017-05-20" @default.
• W2761911056 modified "2023-09-24" @default.
• W2761911056 title "A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP)." @default.
• W2761911056 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15753" @default.
• W2761911056 hasPublicationYear "2017" @default.
• W2761911056 type Work @default.
• W2761911056 sameAs 2761911056 @default.
• W2761911056 citedByCount "17" @default.
• W2761911056 countsByYear W27619110562017 @default.
• W2761911056 countsByYear W27619110562018 @default.
• W2761911056 countsByYear W27619110562019 @default.
• W2761911056 countsByYear W27619110562020 @default.
• W2761911056 countsByYear W27619110562021 @default.
• W2761911056 countsByYear W27619110562023 @default.
• W2761911056 crossrefType "journal-article" @default.
• W2761911056 hasAuthorship W2761911056A5001331899 @default.
• W2761911056 hasAuthorship W2761911056A5004814161 @default.
• W2761911056 hasAuthorship W2761911056A5005883267 @default.
• W2761911056 hasAuthorship W2761911056A5033837903 @default.
• W2761911056 hasAuthorship W2761911056A5041071225 @default.
• W2761911056 hasAuthorship W2761911056A5052490557 @default.
• W2761911056 hasAuthorship W2761911056A5054288328 @default.
• W2761911056 hasAuthorship W2761911056A5056309801 @default.
• W2761911056 hasAuthorship W2761911056A5081369976 @default.
• W2761911056 hasConcept C121608353 @default.
• W2761911056 hasConcept C126322002 @default.
• W2761911056 hasConcept C143998085 @default.
• W2761911056 hasConcept C2776694085 @default.
• W2761911056 hasConcept C2777701055 @default.
• W2761911056 hasConcept C2778594517 @default.
• W2761911056 hasConcept C2780057760 @default.
• W2761911056 hasConcept C71924100 @default.
• W2761911056 hasConcept C90924648 @default.
• W2761911056 hasConceptScore W2761911056C121608353 @default.
• W2761911056 hasConceptScore W2761911056C126322002 @default.
• W2761911056 hasConceptScore W2761911056C143998085 @default.
• W2761911056 hasConceptScore W2761911056C2776694085 @default.
• W2761911056 hasConceptScore W2761911056C2777701055 @default.
• W2761911056 hasConceptScore W2761911056C2778594517 @default.
• W2761911056 hasConceptScore W2761911056C2780057760 @default.
• W2761911056 hasConceptScore W2761911056C71924100 @default.
• W2761911056 hasConceptScore W2761911056C90924648 @default.
• W2761911056 hasIssue "15_suppl" @default.
• W2761911056 hasLocation W27619110561 @default.
• W2761911056 hasOpenAccess W2761911056 @default.
• W2761911056 hasPrimaryLocation W27619110561 @default.
• W2761911056 hasRelatedWork W2796582438 @default.
• W2761911056 hasRelatedWork W2892640821 @default.
• W2761911056 hasRelatedWork W2948845624 @default.
• W2761911056 hasRelatedWork W2987628800 @default.
• W2761911056 hasRelatedWork W3151327641 @default.
• W2761911056 hasRelatedWork W3205275432 @default.
• W2761911056 hasRelatedWork W4228997304 @default.
• W2761911056 hasRelatedWork W4247922271 @default.
• W2761911056 hasRelatedWork W4255240967 @default.
• W2761911056 hasRelatedWork W4283526032 @default.
• W2761911056 hasVolume "35" @default.
• W2761911056 isParatext "false" @default.
• W2761911056 isRetracted "false" @default.
• W2761911056 magId "2761911056" @default.
• W2761911056 workType "article" @default.